IKNA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs...

Stats
Šios dienos apimtis	315 259
Vidutinė apimtis	393 849
Rinkos kapitalizacija	63.70M
EPS	$0 ( 2024-03-12 )
Kita pelno data	( $-0.400 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.810
ATR14	$0.00600 (0.46%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Germa Caroline	Buy	579 100	Stock Option (Right to Buy)
2024-02-29	Germa Caroline	Buy	0
2024-02-01	Ecsedy Jeffrey	Buy	100 000	Stock Option (Right to Buy)
2024-02-01	Marango Jotin	Buy	181 000	Stock Option (Right to Buy)
2024-02-01	Manfredi Mark	Buy	320 000	Stock Option (Right to Buy)

INSIDER POWER
96.04
Last 94 transactions
Buy: 20 809 745 \| Sell: 873 348

Tūris Koreliacija

Ilgas: -0.15 (neutral)

Trumpas: -0.60 (weak negative)

Signal:(48.423) Neutral

Ikena Oncology, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
RMRM	0.946
APOP	0.919
CMPO	0.909
XLRN	0.907
CVT	0.903
BRACU	0.902
NVCN	0.9
PAIC	0.896
WTMA	0.894
TRHC	0.889

10 Labiausiai neigiamai susiję koreliacijos
BOCH	-0.939
MMAC	-0.917
NETE	-0.902
NAKD	-0.893
HFWA	-0.892
SYBT	-0.882
VIEW	-0.879
GRIN	-0.878
RPRX	-0.878
AHPI	-0.878

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Ikena Oncology, Inc. Koreliacija - Valiuta/Žaliavos

-0.24
( neutral )

-0.02
( neutral )

0.00
( neutral )

0.47
( neutral )

Ikena Oncology, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$9.16M
Bruto pelnas:	$8.14M (88.86 %)
EPS:	$-1.630

FY	2023
Pajamos:	$9.16M
Bruto pelnas:	$8.14M (88.86 %)
EPS:	$-1.630

FY	2022
Pajamos:	$15.62M
Bruto pelnas:	$13.58M (86.98 %)
EPS:	$-1.840

FY	2021
Pajamos:	$30.99M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.951

Financial Reports:

No articles found.

Ikena Oncology, Inc.

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.